By the judgement handed down in Aspen v AGCM [1], the Regional Administrative Court of Latium (the Court) has recently determined the appeal lodged by a South African manufacturer of generic drugs, Aspen, against the 2016 decision made by Italian Competition Authority (ICA), rejected all the grounds of appeal. As is known, the ICA found Aspen to have infringed Article 102 TFEU by imposing excessive prices on the Italian national health system (INHS) for the supply of several anti-cancer drugs, the so-called ‘Cosmos drugs’ [2]. The facts of the case The so-called Cosmos drugs included various medicines produced with different active ingredients whose essential therapeutic function was to treat cancer pathologies, especially those affecting younger and older patients. In 2009 the
Share on
|
|
The Italian Regional Administrative Court for Latium upholds the infringement decision made by the Competition Authority against a pharmaceutical laboratory for excessive pricing (Aspen)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
